Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new EU Horizons project, which involves Professor Trevor Sharp in Pharmacology, aims to train the next generation of serotonin researchers and deliver new fundamental insights in how early life changes in serotonin caused by genetic or environmental factors alter brain development and thereby contribute to the cause of serotonergic psychiatric disorders. These new insights have the potential to reveal novel targets for future therapies, as well as the developmental windows in which such interventions would be most effective.

This multi-disciplinary project, led by Professor Judith Homberg of Translational Neuroscience at Radboudumc, brings together researchers from leading European universities and institutes to create a network with world-leading expertise in serotonin research and training. Together, these partners will train fifteen talented PhD-students to lead research in serotonin, neural development and psychiatry in the years ahead. Applications for a DPhil place in the Sharp group, as part of this project can be made online at https://www.serotonin-and-beyond-project.eu/

Similar stories

Vasudevan lab identifies novel means of improving sensitivity and efficiency for PCR COVID testing

Department Vasudevan Group

In collaboration with the infectious disease units at the John Radcliffe and Churchill Hospitals, the Vasudevan lab has identified a novel means of improving RT-qPCR sensitivity and efficiency for the detection of SARS-CoV-2 through the concentration of pooled patient lysates.

International collaboration by Potter group uncovers vital element in regulation of Na⁺/K⁺- ATPase-α1

Department

An international collaboration of the Potter Group with Solomon Snyder’s Group in the USA and with Chinese and German colleagues has uncovered the myo-inositol polyphosphate pyrophosphate 5-InsP7 as a regulator of the Na⁺/K⁺- ATPase-α1

Professor Angela Russell receives 2021 Harrington UK Rare Disease Scholar Award

Department Russell Group

Angela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).

Professor Fran Platt appointed as new Head of Department of Pharmacology

Department

Professor Fran Platt has been appointed as the new Head of Department for Pharmacology at the University of Oxford. Fran took up her new post with effect from 1 June 2020 and will serve for an initial period of five years.

The Department mourns the loss of three greats in neuropharmacology

Department

This summer three of the world’s most distinguished neurochemists died; each was a member of the Department during their outstanding scientific careers.

Professor Fran Platt secures £1M funding over two years for vital Parkinson's Disease research, in collaboration with Pfizer

Department

There is an increasing body of genetic and biochemical evidence that points toward lysosomal dysfunction as a risk factor for developing age-related neurodegenerative disorders, including Parkinson’s disease (PD).